Fanciulli Giuseppe, Dettori Alessandra, Fenude Emma, Demontis Maria Piera, Alberico Elisabetta, Delitala Giuseppe, Anania Vittorio
Dipartimento-Struttura Clinica Medica-Patologia Speciale Medica, Istituto di Patologia Medica, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.
Pharmacol Res. 2003 Jan;47(1):53-8. doi: 10.1016/s1043-6618(02)00267-0.
Gluten Exorphin B5 (GE-B5) is a food-derived opioid peptide, identified in vitro in enzymatic digests of wheat gluten. It has been suggested that this peptide may play a regulatory role on pituitary secretion, since it stimulates prolactin (PRL) secretion when administered in the cerebral ventricles in rats. It is not known, however, if GE-B5 can exert this stimulatory action after peripheral administration. In order to clarify this aspect, we gave the following treatments to four groups of male rats: intravenous (i.v.) vehicle, GE-B5 3 mg/kg body weight i.v., naloxone intraperitoneally (i.p.) followed by vehicle i.v., naloxone i.p. followed by GE-B5 i.v. Blood samples for PRL were taken at intervals for 60 min after vehicle or GE-B5 administration. At the dose of 3 mg/kg body weight, GE-B5 induced a significant increase in PRL levels; naloxone completely abolished any effect of GE-B5 on PRL secretion. The present study indicates that GE-B5 stimulates PRL secretion after peripheral administration and that its action is mediated via classical opioid receptors; moreover, it identifies the minimum peptide dose which must reach the blood in order to exert its action on PRL secretion.